Screener
Spyre Therapeutics, Inc. SYRE Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value |
|---|---|---|---|---|
| Money market funds | $95,448 | — | — | $95,448 |
| Total cash equivalents | $95,448 | — | — | $95,448 |
| Marketable securities: | ||||
| Commercial paper | $164,635 | $1 | $(230) | $164,406 |
| Corporate bonds | 86,788 | 17 | (149) | 86,656 |
| U.S. government treasury securities | 257,224 | 252 | (296) | 257,180 |
| U.S. government agency securities | 136,402 | 20 | (382) | 136,040 |
| Total marketable securities | $645,049 | $290 | $(1,057) | $644,282 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s cumulative cost basis?
- Spyre Therapeutics, Inc. (SYRE) reported cumulative cost basis of $645.05M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s cumulative cost basis changed year-over-year?
- Spyre Therapeutics, Inc.'s cumulative cost basis increased by 25.1% year-over-year, from $515.68M to $645.05M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s cumulative cost basis?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s cumulative cost basis has grown at a 217.8% compound annual growth rate (CAGR), from $20.88M to $669.94M.
Ask your AI about Spyre Therapeutics, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude